Nona Biosciences, a global biotechnology company, has entered into an exclusive license agreement with Pfizer for the global clinical development and commercialization of Nona Biosciences’ MSLN-targeted antibody-drug conjugate (ADC), HBM9033.
 
Nona Biosciences will receive a total of up to $53 million in upfront and near-term payments, with the potential for additional payments of up to $1.05 billion based on development and commercial milestones. Nona Biosciences is also eligible to receive royalties on sales.
 
HBM9033 is an ADC drug that specifically targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in HBM9033 is derived from the Harbour Mice platform. The design of the mAb ensures superior potency and safety in various preclinical tumor models and has potential as a best-in-class therapeutic option.
 
“We are delighted to collaborate with Pfizer, a company that is committed to developing high-impact medicines for people living with cancer,” said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. “This agreement represents a significant milestone in the advancement of our proprietary Harbour Mice platform and the ADC ecosystem, affirming Nona’s robust capabilities and expertise in antibody discovery and development.”